First Time Loading...

GeneDx Holdings Corp
NASDAQ:WGS

Watchlist Manager
GeneDx Holdings Corp Logo
GeneDx Holdings Corp
NASDAQ:WGS
Watchlist
Price: 21.16 USD -0.89% Market Closed
Updated: May 16, 2024

Intrinsic Value

GeneDx Holdings Corp. is a patient centered health intelligence company. [ Read More ]

The intrinsic value of one WGS stock under the Base Case scenario is 13.66 USD. Compared to the current market price of 21.16 USD, GeneDx Holdings Corp is Overvalued by 35%.

Key Points:
WGS Intrinsic Value
Base Case
13.66 USD
Overvaluation 35%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
GeneDx Holdings Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling WGS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
GeneDx Holdings Corp

Provide an overview of the primary business activities
of GeneDx Holdings Corp.

What unique competitive advantages
does GeneDx Holdings Corp hold over its rivals?

What risks and challenges
does GeneDx Holdings Corp face in the near future?

Has there been any significant insider trading activity
in GeneDx Holdings Corp recently?

Summarize the latest earnings call
of GeneDx Holdings Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for GeneDx Holdings Corp.

Provide P/S
for GeneDx Holdings Corp.

Provide P/E
for GeneDx Holdings Corp.

Provide P/OCF
for GeneDx Holdings Corp.

Provide P/FCFE
for GeneDx Holdings Corp.

Provide P/B
for GeneDx Holdings Corp.

Provide EV/S
for GeneDx Holdings Corp.

Provide EV/GP
for GeneDx Holdings Corp.

Provide EV/EBITDA
for GeneDx Holdings Corp.

Provide EV/EBIT
for GeneDx Holdings Corp.

Provide EV/OCF
for GeneDx Holdings Corp.

Provide EV/FCFF
for GeneDx Holdings Corp.

Provide EV/IC
for GeneDx Holdings Corp.

Show me price targets
for GeneDx Holdings Corp made by professional analysts.

What are the Revenue projections
for GeneDx Holdings Corp?

How accurate were the past Revenue estimates
for GeneDx Holdings Corp?

What are the Net Income projections
for GeneDx Holdings Corp?

How accurate were the past Net Income estimates
for GeneDx Holdings Corp?

What are the EPS projections
for GeneDx Holdings Corp?

How accurate were the past EPS estimates
for GeneDx Holdings Corp?

What are the EBIT projections
for GeneDx Holdings Corp?

How accurate were the past EBIT estimates
for GeneDx Holdings Corp?

Compare the revenue forecasts
for GeneDx Holdings Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of GeneDx Holdings Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of GeneDx Holdings Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of GeneDx Holdings Corp compared to its peers.

Compare the P/E ratios
of GeneDx Holdings Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing GeneDx Holdings Corp with its peers.

Analyze the financial leverage
of GeneDx Holdings Corp compared to its main competitors.

Show all profitability ratios
for GeneDx Holdings Corp.

Provide ROE
for GeneDx Holdings Corp.

Provide ROA
for GeneDx Holdings Corp.

Provide ROIC
for GeneDx Holdings Corp.

Provide ROCE
for GeneDx Holdings Corp.

Provide Gross Margin
for GeneDx Holdings Corp.

Provide Operating Margin
for GeneDx Holdings Corp.

Provide Net Margin
for GeneDx Holdings Corp.

Provide FCF Margin
for GeneDx Holdings Corp.

Show all solvency ratios
for GeneDx Holdings Corp.

Provide D/E Ratio
for GeneDx Holdings Corp.

Provide D/A Ratio
for GeneDx Holdings Corp.

Provide Interest Coverage Ratio
for GeneDx Holdings Corp.

Provide Altman Z-Score Ratio
for GeneDx Holdings Corp.

Provide Quick Ratio
for GeneDx Holdings Corp.

Provide Current Ratio
for GeneDx Holdings Corp.

Provide Cash Ratio
for GeneDx Holdings Corp.

What is the historical Revenue growth
over the last 5 years for GeneDx Holdings Corp?

What is the historical Net Income growth
over the last 5 years for GeneDx Holdings Corp?

What is the current Free Cash Flow
of GeneDx Holdings Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for GeneDx Holdings Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
GeneDx Holdings Corp

Current Assets 163.4m
Cash & Short-Term Investments 112.9m
Receivables 28.9m
Other Current Assets 21.6m
Non-Current Assets 231.1m
PP&E 57.6m
Intangibles 169.1m
Other Non-Current Assets 4.4m
Current Liabilities 50.7m
Accounts Payable 9.5m
Accrued Liabilities 38.3m
Other Current Liabilities 2.9m
Non-Current Liabilities 136.6m
Long-Term Debt 52.3m
Other Non-Current Liabilities 84.3m
Efficiency

Earnings Waterfall
GeneDx Holdings Corp

Revenue
221.9m USD
Cost of Revenue
-109.7m USD
Gross Profit
112.2m USD
Operating Expenses
-237.8m USD
Operating Income
-125.6m USD
Other Expenses
-9.4m USD
Net Income
-135m USD

Free Cash Flow Analysis
GeneDx Holdings Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

WGS Profitability Score
Profitability Due Diligence

GeneDx Holdings Corp's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
20/100
Profitability
Score

GeneDx Holdings Corp's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

WGS Solvency Score
Solvency Due Diligence

GeneDx Holdings Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
45/100
Solvency
Score

GeneDx Holdings Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

WGS Price Targets Summary
GeneDx Holdings Corp

Wall Street analysts forecast WGS stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for WGS is 15.56 USD with a low forecast of 5.56 USD and a high forecast of 25.2 USD.

Lowest
Price Target
5.56 USD
74% Downside
Average
Price Target
15.56 USD
26% Downside
Highest
Price Target
25.2 USD
19% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

WGS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

WGS Price
GeneDx Holdings Corp

1M 1M
+120%
6M 6M
+1 339%
1Y 1Y
+235%
3Y 3Y
-94%
5Y 5Y
-93%
10Y 10Y
-93%
Annual Price Range
21.16
52w Low
1.24
52w High
23.38
Price Metrics
Average Annual Return -47.25%
Standard Deviation of Annual Returns 52.55%
Max Drawdown -100%
Shares Statistics
Market Capitalization 552.7m USD
Shares Outstanding 25 978 863
Percentage of Shares Shorted 12.75%

WGS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

GeneDx Holdings Corp Logo
GeneDx Holdings Corp

Country

United States of America

Industry

Health Care

Market Cap

552.7m USD

Dividend Yield

0%

Description

GeneDx Holdings Corp. is a patient centered health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,200 full-time employees. The company went IPO on 2020-09-04. The firm is engaged in accelerating the use of genomic and clinical information to enable precision medicine as the standard of care. The firm is also engaged in transforming healthcare through its exome and genome testing and interpretation, fueled by rare disease data sets. Its health information platform, Centrellis, which integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data. Its products and services include Exome & genome testing, Test catalog and Genetic counseling. The company offers two types of tests that examine a patient’s deoxyribonucleic acid (DNA), which include genome sequencing (GS/WGS) and exome sequencing (ES/WES). The company offers tests for neurodevelopmental disorders, cardiology, oncology and others.

Contact

CONNECTICUT
Stamford
333 Ludlow Street, North Tower, 8Th Floor
+16177808742
https://sema4.com/

IPO

2020-09-04

Employees

1 200

Officers

President, CEO & Director
Ms. Katherine A. Stueland
Chief Financial Officer
Mr. Kevin Feeley
Senior VP & Head of Operations
Ms. Karen Ponchner
Chief Product & Technology Officer
Mr. Eric Olivares Ph.D.
General Counsel
Mr. Devin K. Schaffer J.D., M.B.A.
Chief Medical Officer
Mr. Paul Kruszka M.D.
Show More
Chief Growth Officer
Ms. Melanie Duquette
Chief of Staff
Sabrina Dunbar
Show Less

See Also

Discover More
What is the Intrinsic Value of one WGS stock?

The intrinsic value of one WGS stock under the Base Case scenario is 13.66 USD.

Is WGS stock undervalued or overvalued?

Compared to the current market price of 21.16 USD, GeneDx Holdings Corp is Overvalued by 35%.